<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940816-0-00005</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  August 16, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4700 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Food and Drug Administration</USBUREAU> <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>21 CFR Part 558</RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> New Animal Drugs For Use In Animal Feeds; Tiamulin  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Final rule. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect the approval of a supplemental new animal drug application (NADA) filed by Fermenta Animal Health Co. The supplemental NADA provides for the use of tiamulin (Denagard <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=6 f=2 --> &reg; <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> ) Type A medicated article to make a Type C medicated feed used for the treatment of swine dysentery. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  August 16, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  George K. Haibel, Center for Veterinary Medicine (HFV&hyph;133), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;1644. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Fermenta Animal Health Co., 10150 North Executive Hills Blvd., Kansas City, MO 64153, is the sponsor of NADA 139&hyph;472, which was approved on July 17, 1987 (52 FR 26955), for the use of tiamulin Type A medicated articles in the preparation of Type C medicated swine feeds. As first approved, the Type C medicated feed containing 35 grams per ton (g/t) of tiamulin could be used to control swine dysentery. The Type C medicated feed containing 10 g of tiamulin per ton could be used for increased rate of weight gain from weaning to 56.70 kilograms (kg) (125 pounds (lb)), which was later approved to 113.40 kg (250 lb) on October 6, 1988 (53 FR 39257). The sponsor has submitted a supplemental application providing for the use of tiamulin Type A medicated article containing 5, 10, or 113.4 g/lb of tiamulin hydrogen fumarate to make a Type C medicated swine feed containing 200 g/t of tiamulin for the treatment of swine dysentery.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The supplemental NADA is approved as of July 7, 1994, and the regulations are amended by modifying &sect;558.600 (21 CFR 558.600) to reflect the approval. The basis for approval is discussed in the freedom of information summary. In addition, the regulation is amended by modifying the genera `` <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Treponema <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> '' to include the currently scientifically accepted genera name `` <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Serpulina <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> .''  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Under section 512(c)(2)(F)(iii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(iii)), this approval qualifies for 3 years exclusivity beginning July 7, 1994, because the supplemental application contains reports of new clinical or field investigations (other than bioequivalence or residue studies) essential to the approval of the application and conducted by the applicant. The 3 years of marketing exclusivity applies only to the new claim ``for treatment of swine dysentery'' for which the supplemental application was approved.  <!-- PJG 0012 frnewline --> In accordance with the freedom of information provisions of part 20 (21 CFR part 20) and &sect;514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline --> The agency has carefully considered the potential environmental effects of this action. FDA has concluded that the action will not have a significant impact on the human environment, and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting that finding, contained in an environmental assessment, may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> List of Subjects in 21 CFR Part 558  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Animal drugs, Animal feeds. <!-- PJG 0012 frnewline --> Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is amended as follows: <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 558_NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 1. The authority citation for 21 CFR part 558 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority: <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  Secs. 512, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b, 371). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 2. Section 558.600 Tiamulin is amended in paragraph (c)(1)(i) by removing the word `` <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Treponema <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> '' and adding in its place the words `` <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Serpulina (Treponema) <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> '' and by adding new paragraph (c)(3) to read as follows: <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;558.600  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Tiamulin.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * * <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (c) * * * <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Amount <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . 200 grams of tiamulin per ton. <!-- PJG 0012 frnewline --> (i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Indications for use <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Treatment of swine dysentery associated with  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Serpulina (Treponema) hyodysenteriae <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  susceptible to tiamulin.  <!-- PJG 0012 frnewline --> (ii)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Limitations <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Feed continuously as the sole feed for 14 consecutive days. Withdraw feed 7 days before slaughter. Not for use in swine over 113.40 kilograms (250 pounds) body weight. Use as the only source of tiamulin. Swine being treated with tiamulin should not have access to feeds containing polyether ionophores (e.g., monensin, lasalocid, narasin, semduramicin, or salinomycin) as adverse reactions may occur. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: August 8, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Robert C. Livingston, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;19935 Filed 8&hyph;15&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG /STAG --></p>
		</main>
</body></html>
            